HELLO CHINA

INDUSTRY CLUSTER · Biomedicine

Beijing Daxing medical devices

Daxing links the development and production of regenerative materials, in-vitro diagnostics and vascular-intervention devices with prototyping, regulatory advice, testing and clinical collaboration. Its value is a nearby network for product definition, engineering validation and regulated transfer rather than a simple list of manufacturers.

Formation and regional foundations

Zhongguancun policies, sustained development of the biomedical base, a specialist device park and municipal-district review services shaped the cluster. Public records for 2025 also identify a prototyping platform, an innovation service station and hospital-industry matching that help early research enter manufacturable, testable and registrable pathways.

The Daxing biomedical base and Zhongguancun high-end medical-device park concentrate research, prototypes, operating sites and shared services around Qingfeng West and Yongwang West roads. Clinical, review and research resources participate through the wider Beijing network. Products include mineralised-collagen bone repair, absorbable haemostatic materials, in-vitro diagnostic reagents and instruments, aortic stent grafts and associated guidewires and catheters. Their risks and evidence routes differ greatly, so cooperation follows a named model, intended use, registration market and change responsibility.

Core geography: Daxing biomedical base, Zhongguancun high-end medical-device park, and clinical-regulatory services

Beijing Daxing medical-device translation network

Specialist park, prototypes, product firms, innovation services and customers

Nodes show collaboration; registered and licensed entities and addresses define compliance.

  • Zhongguancun high-end medical-device park — Design, prototypes, risk, validation, registration and production connect.
  • Daxing prototype and process support — Medical materials, precision work, electronics, optics, cleanrooms and sterilisation support prototypes.
  • Allgens Daxing base — Bone repair and absorbable haemostatic materials represent material-based devices.
  • Drug and device innovation service station — Registration, quality, testing and filing questions follow a named model.
  • Hotgen Daxing base — IVD reagents and instruments connect specimens, assay versions, performance and lab use.
  • Percutek Daxing operating site — Stent graft, guidewire and catheter work requires compatibility, clinical use and post-market duties.

01 · How the specialist park, biomedical base and wider Beijing network interact

Daxing gathers firms and production services while clinical, research and review resources cross the park boundary.

Zhongguancun policy, continued development of the Daxing biomedical base, a specialist device park and municipal-district innovation services let start-ups, growing manufacturers, prototype services and laboratories interact in a concentrated area. This lowers friction in finding people, space, suppliers and regulatory guidance, but does not shorten required risk management, validation or clinical evidence. Entering the park never means a product is approved.

The Qingfeng West and Yongwang West area concentrates the park, operating sites and services, but a firm’s registration, research, quality, manufacturing and storage addresses may differ. Model review uses registration, production licensing, technical requirements and quality documents to identify each address’s function. A showroom, research office or pilot line does not automatically represent the plant making commercial lots.

Medical-device translation needs clinical departments to define unmet needs, research and engineering teams to form solutions, laboratories to evaluate performance and regulatory routes to assess evidence. These resources are distributed across Beijing rather than all inside Daxing. Hospital or research cooperation also needs ethics, data, specimens, result ownership and conflict management. Proximity improves communication but does not automatically make a study valid product evidence.

  • Zhongguancun policy, the biomedical base, specialist park and review services form the environment.
  • Operating sites and shared services gather near Qingfeng West and Yongwang West roads.
  • Hospitals, research institutions and reviewers participate across Beijing, not all inside Daxing.

02 · Why material, diagnostic and implantable devices need different routes

Intended use, body contact, specimens and energy determine the validation combination.

Mineralised-collagen bone repair and absorbable haemostatic materials depend on input source, composition, microstructure, pore or fibre features, moisture, mechanics, absorption and sterilisation effects. Prototypes may vary material and structure, but once validation and registration evidence exist, changes in critical inputs, ratio, forming, drying, packing or sterilisation require impact assessment. Similar appearance does not make a material supplier freely interchangeable.

IVD performance depends on analyte, specimen, collection tube, pretreatment, calibrators, lot, stability and instrument assay version. Instruments add optics, heat, sampling, algorithms, maintenance and quality control. Sensitivity, specificity, precision or range is evaluated with the registered specimen and reagent-instrument combination. Laboratory centrifugation, storage, handling and quality control can also alter results, so not every deviation belongs to the reagent.

Aortic stent grafts and guidewire-catheter systems used in intervention require combined validation of graft and frame materials, size matrix, radial support, fatigue, sealing, release and delivery compatibility. Guidewire diameter, length, coating, support and control, plus catheter kink, push, visibility and connections, affect use. Components are selected by approved scope, product code and instructions rather than similar names.

  • Bone repair and haemostatic materials require composition, structure, biological performance, absorption and sterilisation.
  • IVD performance follows specimens, analytes, assay versions and laboratory conditions.
  • Stent grafts, guidewires and catheters need dimensions, materials, delivery, compatibility and clinical use.

03 · How medical materials, precision work, cleanrooms and sterilisation connect

A product crosses several specialists, while the manufacturer remains responsible for the full change chain.

Bone-repair materials may need collagen, inorganic salts or other medical-grade inputs, forming and drying. Implants can depend on metals or polymers, precision tubing and machining, surface treatment, textile or graft work and assembly. IVD instruments add electronics, optics, fluidics, software and references. Specialists may be located elsewhere, while Daxing firms integrate design, critical processes, quality and release; geographic clustering does not make the supply chain local-only.

Cleanroom class, pressure, climate, particles and microbes follow product and process risk and connect to people and material flow, sanitation, maintenance and deviations. Sterile-product packaging must survive the intended sterilisation, transport and shelf life; the cycle needs validated loading, parameters, sterility assurance and residual or material effects. Outsourced sterilisation does not transfer responsibility: the manufacturer qualifies the service, approves the process and links each record to release.

Changing a critical material, part, electronic module, software library, package, steriliser or test method may alter composition, impurities, dimensional distribution, surface, life, compatibility or algorithm behaviour even when a datasheet looks equal. Change assessment traces impact through design inputs, risk controls, process, validation, stability, registration and released goods, then decides tests, filings and inventory. An alternative enters the approved list only after this work.

  • Medical materials, precision work, electronics, optics and cleanrooms are distinct capabilities.
  • Packaging, sterilisation, references, tests, clinical and regulatory services span development and market.
  • A second source needs equivalence and impact assessment, not only a datasheet.

04 · Aligning registration, intended use, lot release and vigilance

A named model is needed to state what a product may do and who is responsible.

Buyers align registrant, product name, model, structure and composition, intended use, accessories and manufacturing address across registration, quotation, labels, instructions, packaging and physical identifiers. Models under one brand can differ in performance, components and use. A function approved elsewhere or still under development is not automatically within the Chinese registration. Demonstrations using development software or unapproved accessories must be clearly separated from the deliverable product.

Production licensing and the quality system must cover the actual product and address. Lot release reviews inputs, critical process, environment, in-process and final tests, packaging, sterilisation or calibration and deviations. Sterile devices trace to steriliser loading and release; instruments to calibration, electrical safety, software and configuration; reagents to inputs, formulation, filling, stability and lot performance. A generic certificate cannot replace those records.

When a healthcare provider or laboratory sees instrument failure, catheter damage, implant abnormality, reagent drift or result risk, it preserves unique or lot identity, environment, companion products, operation, relevant patient or specimen information and outcome, then moves the case through distribution to the registrant. The registrant assesses risk, investigates returns and records, and decides reporting, correction, safety information or recall. Multiple distribution tiers must not break contact or timelines.

  • Registrant, name, model, composition and intended use must correspond.
  • Production, quality, changes, sterilisation or calibration and release are product-specific.
  • Healthcare, distribution and manufacturing vigilance and recall duties need traceability.

05 · Connecting design history, verification, batch records and unique identification

Digital records retain decisions, versions and approvals and connect market issues back to design and production.

Design history converts clinical need into intended use, user, environment, material or structure, performance, safety and usability inputs, then links each to risk controls, outputs, verification methods, sample versions, criteria and results. When a requirement changes, affected drawings, processes, software, risks and tests become visible for authorised review and approval. Digital links help find relationships but do not decide clinical meaning or regulatory sufficiency.

Production equipment, tooling, measurement, clean environments, materials and people may link to batch records by code, while electronic records also preserve identity, time, original data, audit trails and signatures. IVD assay menus, software and algorithm versions correspond to reagent lots, quality control and user environments; unique device identification connects model and production information to post-market service. Manual entry or exception release retains reason and approval rather than rewriting the original.

Unique or lot identity can connect complaints, service replacements, reagent failures, adverse events and recalls to production, supplier lots, sterilisation or calibration and design version. Analysis may reveal trends by model, material lot, use or time. Those trends return to risk management, post-market surveillance, design review and supplier control to decide improvements in design, process, instructions or safety information. Healthcare and distribution data still require patient, customer and commercial protection.

  • Design inputs, risk controls, verification cases and results need traceability.
  • Equipment, environment, batch records, assay versions and identifiers require change control.
  • Complaints, service, vigilance and recall data return to risk and design review.

06 · How providers, laboratories, distributors and overseas partners divide work

Customers buy devices together with evidence, training, installation, consumables and continuing service.

Hospitals using bone repair, haemostatic or implantable products connect registered use with patient selection, procedure, instruments, sterile handling, stock and expiry, staff training and follow-up. Diagnostic laboratories also assess specimen volume, throughput, time, calibration and quality control, reagent lots, information links and service downtime. Procurement should test the real department workflow rather than compare only instrument specifications or per-test cost.

Device distributors and service firms may manage stock, cold or controlled transport, hospital receiving, installation and calibration, training, preventive maintenance, spares, complaints and vigilance transfer. They must not independently change labels, instructions, packages, software or assay menus or use critical non-original parts without the registrant. Dispatch records preserve model, unique or lot identity, quantity, recipient and date so safety information and recall can reach the final site.

An overseas partner first confirms classification, technical files, clinical or performance evidence, manufacturing sites, quality system, local responsible entity, language and identification in the destination, then decides what Chinese evidence can be used and what must be added. After registration, import, storage, installation, service, vigilance, safety notices and recall duties are assigned. A sales network without regulatory and technical capacity may not be able to carry them.

  • Providers and laboratories care about intended use, workflow, training, quality control and response.
  • Distributors maintain storage, installation, identity, complaints and recall links.
  • Overseas partners need destination registration, local responsibility, labels and vigilance.

07 · Risks in clinical evidence, registration, changes, sterility and intellectual property

Low price or speed cannot come from reduced validation, hidden changes or vague service duty.

Weak clinical evidence may involve too few subjects or events, a population misaligned with the intended indication, a poor comparator, short follow-up, a studied version unlike the market version, or selective reporting. IVD evidence can also fail when specimen mix, disease distribution, reference method or assay version does not support a new use. Partners work backward from intended use rather than treating publications or project experience as proof of the actual product.

Registration scope is easily misread in accessories, populations, specimen types, sizes, software functions and clinical promotion. Presenting a research or overseas function as domestically registered creates compliance and clinical risk after purchase. Uncontrolled changes in material, process, supplier, address, software, sterilisation or packaging can also move the actual product away from its evidence. Technical, quality and regulatory roles therefore join marketing review and change control.

A low quote may hide substituted medical-grade materials, reduced validation, compressed sterilisation or packaging work, unassessed outsourcing, or omitted calibration, consumables, maintenance and vigilance service. Risk then appears during registration, production, use or post-market. Joint development also assigns rights and uses for clinical needs, drawings, prototypes, processes, code, tests, patents and registration outcomes. Price is comparable only when cost, rights and after-sales sit in one delivery boundary.

  • Clinical or performance evidence must fit intended use, version, population or specimen.
  • Material, process, supplier, software, sterilisation and package changes require assessment.
  • Rights in drawings, prototypes, code, tests and registration results follow contribution and use.

08 · Starting prototype, material or channel work from one intended use

Technical, quality and regulatory staff jointly confirm stage, validation ownership and change boundary.

Early work may be staged across prototypes and tooling, medical-grade material selection, precision processing, preclinical or performance tests, digital quality, cleanrooms, packaging, sterilisation and regulatory advice. Approved products can establish disciplined distribution and service. Each direction has a different stage and duty: an engineering prototype is not a commercially saleable clinical device. The parties first identify research, input supply, validation service or approved-product trade.

A written request states intended use, population or specimen, registration market, stage, standards, material or sample specification, design outputs, risk and validation duty, quantity, delivery, intellectual property and change control. Technical, quality and regulatory leads confirm it together. Responses explain in-house, outsourced and outside-test boundaries and required inputs from the customer, healthcare provider or other institution. An unresolved regulatory path remains an explicit decision, not a hidden assumption in timing.

Prototype or material work can begin with risk review and small-process confirmation, then validate a clearly defined version for performance, biological safety, packaging or sterilisation while retaining samples, raw data, deviations and changes. An approved-product channel trial adds transport, receiving, stock, training, installation or use support, maintenance, complaint transfer and a recall drill. Expansion requires not only a passing product but working documents, response, traceability and responsibility.

  • Prototype, tooling, materials, preclinical tests, digital quality, sterilisation and regulatory support can be staged.
  • Enquiries state intended use, market, stage, standards, material or specimen and validation duty.
  • Approved-product channels trial receiving, training, installation, service, complaints and recall.

Sources and reading notes

Bone repair, haemostatic materials, diagnostic reagents, instruments and implants are not assessed as one category. Each product requires its registration, structure and composition, intended use, manufacturing address, critical materials, sterilisation or calibration, lot release and vigilance responsibilities. Park policies and shared services describe the development environment but never replace model-specific evidence.

  • Beijing public records put Daxing medical-device cluster output at CNY25.01 billion in 2025 and record three newly approved national innovative devices that year, taking the base total to 26.
  • A Daxing public handling report describes local device activity around in-vitro diagnostics, high-value consumables and surgical robots, and records 12 national-level institutions and more than 120 innovation-service platforms.

Related companies

These companies have a locally relevant industry role supported by public information. Order is not a ranking, inclusion does not imply authorization, partnership or endorsement, and Hello China does not participate in or guarantee transactions.

A company may request a free correction or removal through the formal channel if its record is inaccurate or it does not wish to be shown. Do not send business licences, authorization letters or other sensitive files through insecure channels.

  • Allgens — Beijing Municipal Bureau of Economy and Information Technology documents the local base of Beijing Daxing medical devices. A public profile from Shanghai Stock Exchange and Allgens Medical Technology Co., Ltd. records the company's product range and local role in Beijing.
  • Percutek — Beijing Municipal Bureau of Economy and Information Technology documents the local base of Beijing Daxing medical devices. The company’s official site describes related products or services and an operating presence in Beijing.
  • Hotgen — Beijing Municipal Bureau of Economy and Information Technology documents the local base of Beijing Daxing medical devices. The company’s official site describes related products or services and an operating presence in Beijing.
  • Request a company-record correction or removal — Requests are reviewed by a person, handled promptly after verification, free of charge and not tied to commercial cooperation.

Sources

Use the original publishers to check dates, scope and definitions; public material is not a transaction guarantee.